Literature DB >> 20970464

Structure-based design of NS2 mutants for attenuated influenza A virus vaccines.

Hatice Akarsu1, Kiyoko Iwatsuki-Horimoto, Takeshi Noda, Eiryo Kawakami, Hiroaki Katsura, Florence Baudin, Taisuke Horimoto, Yoshihiro Kawaoka.   

Abstract

We previously characterised the matrix 1 (M1)-binding domain of the influenza A virus NS2/nuclear export protein (NEP), reporting a critical role for the tryptophan (W78) residue that is surrounded by a cluster of glutamate residues in the C-terminal region that interacts with the M1 protein (Akarsu et al., 2003). To gain further insight into the functional role of this interaction, here we used reverse genetics to generate a series of A/WSN/33 (H1N1)-based NS2/NEP mutants for W78 or the C-terminal glutamate residues and assessed their effect on virus growth. We found that simultaneous mutations at three positions (E67S/E74S/E75S) of NS2/NEP were important for inhibition of influenza viral polymerase activity, although the W78S mutant and other glutamate mutants with single substitutions were not. In addition, double and triple substitutions in the NS2/NEP glutamine residues, which resulted in the addition of seven amino acids to the C-terminus of NS1 due to gene overlapping, resulted in virus attenuation in mice. Animal studies with this mutant suggest a potential benefit to incorporating these NS mutations into live vaccines.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970464      PMCID: PMC3010430          DOI: 10.1016/j.virusres.2010.10.014

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  62 in total

1.  Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase.

Authors:  S L Tan; M G Katze
Journal:  J Interferon Cytokine Res       Date:  1998-09       Impact factor: 2.607

2.  Influenza virus M1 protein binds to RNA through its nuclear localization signal.

Authors:  C Elster; K Larsen; J Gagnon; R W Ruigrok; F Baudin
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

3.  Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery.

Authors:  Z Chen; Y Li; R M Krug
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

4.  Regulation of eukaryotic protein synthesis: selective influenza viral mRNA translation is mediated by the cellular RNA-binding protein GRSF-1.

Authors:  Y W Park; J Wilusz; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

5.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

6.  Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks.

Authors:  D Kobasa; M E Rodgers; K Wells; Y Kawaoka
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells.

Authors:  E Hatada; S Saito; R Fukuda
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs.

Authors:  M E Nemeroff; S M Barabino; Y Li; W Keller; R M Krug
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

9.  The matrix 1 protein of influenza A virus inhibits the transcriptase activity of a model influenza reporter genome in vivo.

Authors:  D R Perez; R O Donis
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

10.  Multiple alignment comparison of the non-structural genes of influenza A viruses.

Authors:  D L Suarez; M L Perdue
Journal:  Virus Res       Date:  1998-03       Impact factor: 3.303

View more
  7 in total

Review 1.  Recent progress in structure-based anti-influenza drug design.

Authors:  Juan Du; Timothy A Cross; Huan-Xiang Zhou
Journal:  Drug Discov Today       Date:  2012-06-13       Impact factor: 7.851

2.  Adaptive mutations in NEP compensate for defective H5N1 RNA replication in cultured human cells.

Authors:  Benjamin Mänz; Linda Brunotte; Peter Reuther; Martin Schwemmle
Journal:  Nat Commun       Date:  2012-05-01       Impact factor: 14.919

3.  Possibility of cross-species/subtype reassortments in influenza A viruses: an analysis of nonstructural protein variations.

Authors:  Shaomin Yan; Guang Wu
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

4.  Mutations in the M-gene segment can substantially increase replication efficiency of NS1 deletion influenza A virus in MDCK cells.

Authors:  R van Wielink; M M Harmsen; D E Martens; B P H Peeters; R H Wijffels; R J M Moormann
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

5.  Structure-based vaccines provide protection in a mouse model of ehrlichiosis.

Authors:  Sunil Thomas; Nagaraja R Thirumalapura; Patricia A Crocquet-Valdes; Bruce A Luxon; David H Walker
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

Review 6.  Current and emerging cell culture manufacturing technologies for influenza vaccines.

Authors:  Ernest Milián; Amine A Kamen
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

7.  Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine.

Authors:  Hadi Ghaffari; Ahmad Tavakoli; Abdolvahab Moradi; Alijan Tabarraei; Farah Bokharaei-Salim; Masoumeh Zahmatkeshan; Mohammad Farahmand; Davod Javanmard; Seyed Jalal Kiani; Maryam Esghaei; Vahid Pirhajati-Mahabadi; Seyed Hamidreza Monavari; Angila Ataei-Pirkooh
Journal:  J Biomed Sci       Date:  2019-09-10       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.